Does androgen-deprivation therapy for prostate cancer increase the risk for thromboembolic disease?
作者信息
Pinthus Jehonathan H, Duivenvoorden Wilhelmina C
机构信息
Department of Surgery, Division of Urology, McMaster University, Hamilton, ON, Canada.
出版信息
Can Urol Assoc J. 2017 Jan-Feb;11(1-2):39-40. doi: 10.5489/cuaj.4394.
Abstract
摘要
相似文献
1
Does androgen-deprivation therapy for prostate cancer increase the risk for thromboembolic disease?前列腺癌的雄激素剥夺治疗会增加血栓栓塞性疾病的风险吗？
Can Urol Assoc J. 2017 Jan-Feb;11(1-2):39-40. doi: 10.5489/cuaj.4394.
2
A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients.一项关于间歇性雄激素剥夺疗法与连续性雄激素剥夺疗法治疗前列腺癌患者心血管事件的荟萃分析。
Prostate Cancer Prostatic Dis. 2016 Dec;19(4):333-339. doi: 10.1038/pcan.2016.35. Epub 2016 Sep 6.
3
Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapy.接受雄激素剥夺治疗的前列腺癌男性患者发生血栓栓塞性疾病的风险。
BJU Int. 2016 Sep;118(3):391-8. doi: 10.1111/bju.13360. Epub 2015 Nov 19.
4
Serum Lipids prior to Starting Androgen Deprivation Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database.开始雄激素剥夺治疗前的血清脂质与去势抵抗性前列腺癌和转移风险：来自 SEARCH 数据库的结果。
J Urol. 2020 Jan;203(1):120-127. doi: 10.1097/JU.0000000000000494. Epub 2019 Aug 20.
5
The effect of androgen deprivation therapy on periodontal disease in men with prostate cancer.雄激素剥夺疗法对前列腺癌男性患者牙周疾病的影响。
J Urol. 2007 Mar;177(3):921-4. doi: 10.1016/j.juro.2006.10.067.
6
Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer.死亡率与雄激素剥夺疗法作为临床局限性前列腺癌初始治疗后生化复发的挽救性治疗手段
J Urol. 2017 Jun;197(6):1448-1454. doi: 10.1016/j.juro.2016.12.086. Epub 2016 Dec 19.
7
Duration of androgen deprivation therapy and nadir of testosterone at 20 ng/dL predict testosterone recovery to supracastrate level in prostate cancer patients who received external beam radiotherapy.雄激素剥夺治疗的持续时间以及睾酮水平最低点达到20 ng/dL，可预测接受外照射放疗的前列腺癌患者睾酮恢复至去势水平以上。
Int J Urol. 2018 Apr;25(4):352-358. doi: 10.1111/iju.13521. Epub 2018 Jan 11.
8
MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.MDM2抑制以p53依赖的方式使前列腺癌细胞对雄激素剥夺和放疗敏感。
Neoplasia. 2016 Apr;18(4):213-22. doi: 10.1016/j.neo.2016.01.006.
9
Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer.接受原发性雄激素剥夺治疗的临床局限性前列腺癌患者患糖尿病的风险。
J Urol. 2015 Jun;193(6):1956-62. doi: 10.1016/j.juro.2014.12.027. Epub 2014 Dec 15.
10
Androgen Deprivation Therapy Use Increases the Risk of Heart Failure in Patients With Prostate Cancer: A Population-Based Cohort Study.雄激素剥夺疗法会增加前列腺癌患者心力衰竭的风险：基于人群的队列研究。
J Clin Pharmacol. 2019 Mar;59(3):335-343. doi: 10.1002/jcph.1332. Epub 2018 Nov 7.
本文引用的文献
1
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.接受化疗的门诊癌症患者静脉血栓栓塞的一级预防
Cochrane Database Syst Rev. 2016 Dec 1;12(12):CD008500. doi: 10.1002/14651858.CD008500.pub4.
2
Evaluation of US prescription patterns: Are treatment guidelines for cancer-associated venous thromboembolism being followed?美国处方模式评估：癌症相关静脉血栓栓塞的治疗指南是否得到遵循？
Thromb Res. 2016 Sep;145:51-3. doi: 10.1016/j.thromres.2016.07.013. Epub 2016 Jul 26.
3
Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapy.接受雄激素剥夺治疗的前列腺癌男性患者发生血栓栓塞性疾病的风险。
BJU Int. 2016 Sep;118(3):391-8. doi: 10.1111/bju.13360. Epub 2015 Nov 19.
4
Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism.雄激素剥夺疗法治疗前列腺癌与静脉血栓栓塞风险。
Eur Urol. 2016 Jul;70(1):56-61. doi: 10.1016/j.eururo.2015.06.022. Epub 2015 Jun 29.
5
Risk of site-specific cancer in incident venous thromboembolism: a population-based study.初发静脉血栓栓塞症患者特定部位癌症的风险：一项基于人群的研究。
Thromb Res. 2015 Mar;135(3):472-8. doi: 10.1016/j.thromres.2014.12.013. Epub 2014 Dec 16.
6
Thromboelastography identifies hypercoagulablilty and predicts thromboembolic complications in patients with prostate cancer.血栓弹力描记术可识别前列腺癌患者的高凝状态，并预测血栓栓塞并发症。
Thromb Res. 2014 Jan;133(1):88-95. doi: 10.1016/j.thromres.2013.10.007. Epub 2013 Oct 12.
7
Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis.癌症患者静脉血栓栓塞风险：系统评价和荟萃分析。
PLoS Med. 2012;9(7):e1001275. doi: 10.1371/journal.pmed.1001275. Epub 2012 Jul 31.
8
Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism.雄激素剥夺疗法治疗非转移性前列腺癌与外周动脉疾病和静脉血栓栓塞风险增加相关。
Eur Urol. 2012 Jun;61(6):1119-28. doi: 10.1016/j.eururo.2012.01.045. Epub 2012 Feb 1.
9
Androgen deprivation and thromboembolic events in men with prostate cancer.雄激素剥夺与前列腺癌男性的血栓栓塞事件。
Cancer. 2012 Jul 1;118(13):3397-406. doi: 10.1002/cncr.26623. Epub 2011 Nov 9.
10
The role of diethylstilbestrol in the treatment of prostate cancer.己烯雌酚在前列腺癌治疗中的作用。
Urology. 2001 Aug;58(2 Suppl 1):108-13. doi: 10.1016/s0090-4295(01)01252-3.
Zotero 插件